PERSPECTA

News from every angle

← Back to headlines

Soligenix Advances CTCL Research with Positive Study Results

Soligenix (NASDAQ: SNGX) announced progress in its Cutaneous T-Cell Lymphoma (CTCL) research, reporting interim analysis and comparative study results.

18 Apr, 17:40 — 18 Apr, 17:40
PostShare

Sources

Showing 1 of 1 sources
globe-and-mailHigh121d ago

Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results - The Globe and Mail

Soligenix (NASDAQ: SNGX) Advances CTCL Research with Interim Analysis, Comparative Study Results  The Globe and Mail

Read full article →

Related Stories

Veteran Yoruba Actor Ogogo Battles Stage-Four Cancer

28m ago

Hong Kong to Revamp Heat Stress Warning System by Month's End

1h ago

Doctors Remove Record-Breaking 3.1kg Bladder Stone from Man

2h ago

Beginner Tips for Houseplant Care and Gym Workouts

2h ago